Pembrolizumab vs Yttrium Y 90 Ibritumomab Tiuxetan
Pembrolizumab vs Yttrium Y 90 Ibritumomab Tiuxetan: Overview
This comparison examines the pharmacological differences between Pembrolizumab and Yttrium Y 90 Ibritumomab Tiuxetan.
Mechanism of Action
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Pembrolizumab — 26 days.
Chemical Properties
Type: Pembrolizumab — Antibody; Yttrium Y 90 Ibritumomab Tiuxetan — Antibody.